

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor(s): Zoltan Kiss	Examiner:
Appin. No.: 10/582,391	Group Art Unit:
Filing Date: June 9, 2006	Confirmation No.:
Title: METHOD FOR IMPROVING INSULIN SENSITIVITY BY ADMINISTERING AN INHIBITOR OF ANTITRYPSIN	Customer No.: 25764
	Docket No.: 59496 - 336756

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

I CERTIFY THAT THIS CORRESPONDENCE IS BEING ELECTRONICALLY
TRANSMITTED TO THE U.S. PATENT AND TRADEMARK OFFICE ON
DECEMBER 29, 2006.


Amber Freund

INFORMATION DISCLOSURE STATEMENT


In compliance with the duty imposed by 37 C.F.R. 1.56, and in accordance with C.F.R. sections 1.97 *et seq.*, the materials enclosed herewith are brought to the attention of the Examiner as possibly being of interest in connection with the above-identified patent application. Consideration of each of the documents listed on the attached SB/08 form(s) is respectfully requested. The filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is construed to be, prior art or material to the patentability of the present application.

This Information Disclosure Statement is being filed before the receipt of an Office Action on the merits. No fee is believed to be necessary. However, should any fee be required, the Commissioner is authorized to charge our Deposit Account No. 06-0029 and is requested to notify us of the same.

Respectfully submitted,

FAEGRE & BENSON LLP

By:


Tanya S. D'Souza, Reg. No. 56,948
612/766-7835 Customer No.: 25764

Dated: December 29, 2006

Substitute for form 1442-A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number

10/582.391

Filing Date

December 9, 2004

First Named inventor

Zoltan Kiss

Art Unit

Examiner Name: _____

Attorney Docket Number

59496 - 336756

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]Examiner
Signature

Date Considered

EXAMINER Initial (reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * Applicant's unique citation designation number (optional). * See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 601.04. * Enter Office that issued the document, but two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. * Applicant is to place a check mark here if English language is not used.

SEND TO: Commissioner for Patents, P.O. Box 1460, Alexandria, VA 22313-1460

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 4

Complete If Known

Application Number	10/582,391
Filing Date	July 14, 2006
First Named Inventor	Zoltan Kiss
Art Unit	
Examiner Name	
Attorney Docket Number	59496 - 336756

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ‡
		ZIMMET et al., "Global and societal implications of the diabetes epidemic," <i>Nature</i> 414, pp. 782-787, 2001	
		SALTIETL et al., "Insulin signaling and the regulation of glucose and lipid metabolism," <i>Nature</i> 414, pp. 799-806, 2001	
		BELL et al., "Diabetes mellitus and genetically programmed defects in β -cell function," <i>Nature</i> 414, pp. 788-791 2001	
		MATHIS et al., " β -cell death during progression to diabetes," <i>Nature</i> 414, pp. 792-798, 2001	
		SALTIETL, "New perspectives into the molecular pathogenesis and treatment of Type 2 diabetes," <i>Cell</i> 104, pp. 517-529, 2001	
		MOLLER, "New drug targets for Type 2 diabetes and the metabolic syndrome," <i>Nature</i> 414, pp. 821-827, 2001	
		BROWNLEE, "Biochemistry and molecular cell biology of diabetic complications," <i>Nature</i> 414, pp. 813-820, 2001	
		HO et al., "Antioxidants, NF κ B activation, and diabetogenesis," <i>Proc. Soc. Exp. Biol. Med.</i> 222, pp. 205-213, 1999	
		BODEN et al., "FFA cause hepatic insulin resistance by inhibiting suppression of glycogenolysis," <i>Am. J. Physiol. Endocrinol. Metab.</i> 283, pp. E-12-E19, 2001	
		YU et al., "Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase in Muscle," <i>J. Biol. Chem.</i> 277, pp. 50230-50236, 2002	
		MAEDLER et al., "Distinct effects of saturated and monounsaturated fatty acids on β -cell turnover and function," <i>Diabetes</i> 50, pp. 69-76, 2001	
		PRADHAN et al., "C-reactive protein, interleukin 6, and risk of developing Type 2 diabetes mellitus," <i>JAMA</i> , 286, pp. 327-334, 2001	
		THOMPSON et al., "Insulin modulation of acute-phase protein production in a human hepatoma cell line," <i>Cytokine</i> 3, pp. 619-626, 1991	
		CAMPOS et al., "Insulin is a prominent modulator of the cytokine-stimulated expression of acute-phase plasma protein genes," <i>Mol. Cell. Biol.</i> 12, 1789-1797, 1992	
		GANROT et al., "Serum concentration of α_2 -macroglobulin, haptoglobin and α_1 -antitrypsin in diabetes mellitus," <i>Acta Endocrinologica</i> 55, pp. 537-544, 1967	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

†Applicant's unique citation designation number (optional). ‡Applicant is to place a check mark here if English language Translation is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 3

of

4

Complete if Known

Application Number	10/582,391
Filing Date	July 14, 2006
First Named Inventor	Zoltan Kiss
Art Unit	
Examiner Name	
Attorney Docket Number	59496 - 336756

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	γ ²
		MCMILLAN, "Increased levels of acute-phase serum proteins in diabetes," <i>Metabolism</i> 38, pp. 1042-1046, 1989	
		SCHMIDT et al., "Markers of inflammation and prediction of diabetes mellitus in adults," <i>The Lancet</i> 353, pp. 1649-1652, 1999	
		JANCIAUSKIENE, "Conformational properties of serine proteinase inhibitors (serpins) confer multiple pathophysiological roles," <i>Biochim. Biophys. Acta</i> 1535, pp. 221-235, 2001	
		WEWERS et al., "Replacement therapy for alpha ₁ -antitrypsin deficiency associated with emphysema," <i>N. Engl. J. Med.</i> 316, pp. 1055-1062, 1987	
		PERRAUD et al., "Proliferation of rat astrocytes, but not of oligodendrocytes, is stimulated in vitro by protease inhibitors," <i>Int. J. Dev. Neuroscience</i> 6, pp. 261-266, 1988	
		SHE et al., "α ₁ -antitrypsin can increase insulin-induced mitogenesis in various fibroblast and epithelial cell lines," <i>FEBS Lett.</i> 473, pp. 33-36, 2000	
		DABBAGH et al., "Alpha-1-antitrypsin stimulates fibroblast proliferation and procollagen production and activates classical MAP kinase signaling pathways," <i>J. Cell. Physiol.</i> 186, pp. 73-81, 2001	
		GRAZIADEI et al., "The acute phase protein α ₁ -antitrypsin inhibits growth and proliferation of human early erythroid progenitor cells (burst-forming units-erythroid) and of human erythroleukemic cells (K562) in vitro by interfering with transferring iron uptake," <i>Blood</i> 83, pp. 260-268, 1994	
		YAVELOW et al., "α ₁ -antitrypsin blocks the release of transforming growth factor-α from MCF-7 human breast cancer cells," <i>J. Clin. Endocrinol. Metab.</i> 82, pp. 745-752, 1997	
		OZEKI et al., "α ₁ -antitrypsin and hepatic fibrosis," <i>Br. J. Exp. Path.</i> 70, pp. 143-152, 1989	
		GRAZIADEI, "Modulation of iron metabolism in monocytic THP-1 cells and cultured human monocytes by the acute-phase protein α ₁ -antitrypsin," <i>Exp. Hematol.</i> 26, pp. 1053-1060, 1998	
		JANCIAUSKIENE et al., "An interaction between Gemfibrozil and alpha ₁ -antitrypsin," <i>J. Internal Med.</i> 236, pp. 357-360, 1994	
		JANCIAUSKIENE et al., "The interaction of hydrophobic bile acids with the α ₁ -proteinase inhibitor," <i>FEBS Lett.</i> 343, pp. 141-145, 1994	
		JANCIAUSKIENE et al., "In vitro complex formation between cholesterol and α ₁ -proteinase inhibitor," <i>FEBS Lett.</i> 316, pp. 269-272, 1993	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER, initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

